Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Breast cancer monoclonal antibody therapy

Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998 17 2235-2249. [Pg.347]

While no biopharmaceutical is approved with the requirement of genotyping as a part of its therapeutic indication, a recently approved monoclonal antibody therapy against breast cancer, trastuzumab (Herceptin), is indicated only for those tumors measurably expressing the protein expressed by the gene erbB-2. Because the oncogene product of erbB-2 is elevated... [Pg.397]

Leonard DS, Hill AD, Kelly L, Dijkstra B, McDermott E, O Higgins NJ. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br J Surg 2002 89(3) 262-71. [Pg.3481]

Braun, S., Hepp, E., Kentenich, C. R., Janni, W., Pantel, K., Riethmuller, G., Willgeroth, E., and Sommer, H.L. (1999) Monoclonal antibody therapy with edrecolomab in breast cancer patients monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow, Clin Cancer Res 5, 3999-4004. [Pg.1293]

Green MC, Murray JL, Hortobagy GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 2000 26(4) 269-286. Stebbing J, Copson E, O Reilly S. Herceptin in advanced breast cancer. Cancer Treat Rev 2000 26 287-290. [Pg.476]

In the last 2-5 years, selected monoclonal antibodies have become a routine part of care for certain malignancies. Rituximab, a chimeric monoclonal antibody used against CD 20 positive B-cell non-Hodgkin s lymphoma, is now utilized in combination with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone). Trastuzu-mab, a humanized monoclonal antibody, is a weekly maintenance therapy for HER2neu-positive metastatic breast cancer patients. [Pg.390]

B14. Burton, G., Flowers, J., Cox, E., Geisinger, K., Leight, G., Georgiade, G., Dent, G., and McCarty, K., Jr., Monoclonal antiestrogen receptor antibody (H222) in fine needle aspiration cytologies of breast cancer A predictive marker of response to hormonal therapy. Breast Cancer Res. Treat. 6, 164 (1985). [Pg.218]

Trastuzumab (Herceptin) is a humanized monoclonal antibody against the HER2/neu (ErbB-2) member of the epidermal growth factor family of cellular receptors. The internal domain of the HER2/neu glycoprotein encodes a tyrosine kinase that activates downstream signals and enhances metastatic potential and inhibits apoptosis. HER2/neu is overexpressed in up to 30% of breast cancers and is associated with clinical resistance to cytotoxic and hormone therapy. A number of mechanisms of action have... [Pg.701]

Another case of already practical use of pharmacogenetic methods is the test for mutations in tumors that overexpress the human EGFR, HER2. Trastuzumab, a humanized monoclonal antibody, is effective in only 10-15% of breast cancer patients whose tumors overexpress HER2 [67]. Therefore, the pretreatment detection of HER2 is essential for the trastuzumab therapy. [Pg.1473]


See other pages where Breast cancer monoclonal antibody therapy is mentioned: [Pg.224]    [Pg.440]    [Pg.298]    [Pg.122]    [Pg.476]    [Pg.1011]    [Pg.1250]    [Pg.134]    [Pg.367]    [Pg.328]    [Pg.366]    [Pg.461]    [Pg.653]    [Pg.137]    [Pg.267]    [Pg.29]    [Pg.53]    [Pg.400]    [Pg.89]    [Pg.584]    [Pg.422]    [Pg.15]    [Pg.1011]    [Pg.1250]    [Pg.1150]    [Pg.161]    [Pg.107]    [Pg.2340]    [Pg.797]    [Pg.141]    [Pg.1234]    [Pg.1726]    [Pg.970]    [Pg.298]    [Pg.342]    [Pg.322]    [Pg.121]    [Pg.214]    [Pg.799]    [Pg.884]   
See also in sourсe #XX -- [ Pg.573 ]




SEARCH



Antibodies, cancer therapy

Cancer monoclonal antibodies

Monoclonal antibody cancer therapies

Monoclonal antibody therapy

© 2024 chempedia.info